Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity that “remembers” cancer, effectively preventing recurrence. KAIST’s research team has developed an AI-based personalized cancer vaccine design technology that makes this possible and optimizes anticancer effects for each individual.
This article was originally published on MedicalXpress.com

